Related Experiment Video
Updated: May 4, 2026
10:44
Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord
Published on: February 22, 2015
9.9K
Novel therapeutics in multiple sclerosis management: clinical applications
Thomas Leist1, Samuel F Hunter2, Daniel Kantor3
1Associate Professor, Director, Comprehensive Multiple Sclerosis Center, Thomas Jefferson University, Philadelphia, PA.
The American Journal of Medicine
|January 4, 2014
Summary
Multiple sclerosis (MS) management focuses on early intervention with disease-modifying therapies to slow progression and improve quality of life. Continuous research explores novel treatments and personalized approaches for this complex neurological condition.
Area of Science:
- Neuroscience
- Immunology
- Clinical Neurology
Background:
- Multiple sclerosis (MS) impacts approximately 300,000 people in the U.S.
- No cure for MS exists, but disease-modifying therapies can slow progression.
- Early intervention is crucial to prevent irreversible neuronal damage and disability.
Purpose of the Study:
- To review the current state of multiple sclerosis (MS) science.
- To discuss current and emerging therapies for MS.
- To explore physician practices in MS diagnosis and management.
Main Methods:
- Review of current scientific literature on MS.
- Analysis of approved and investigational MS therapies.
- Discussion of clinical trial data and treatment strategies.
Main Results:
- Disease-modifying therapies are available to slow MS progression and improve patient function.
- Ongoing research focuses on neuroprotection and novel agents like oral therapies and monoclonal antibodies.
- Individualized treatment approaches are necessary due to the variable nature of MS.
Conclusions:
- Early and continuous management of MS is vital for delaying disability.
- Personalized therapeutic strategies are essential for optimal MS patient outcomes.
- Further research is needed to refine treatment protocols and long-term efficacy assessments.
More Related Videos
Related Concept Videos
01:19Multiple Sclerosis l: Introduction
20
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
20
01:20Myasthenia Gravis: Overview and Treatment
3.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.7K
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
1.9K
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
1.9K
01:16Therapeutic Drug Monitoring: Overview and Classification
642
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
642
01:24Parkinson's Disease: Treatment
1.4K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.4K
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
755
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
755